9 unchanged sentences
First, the District Court granted Spectrum’s motion for summary judgment of noninfringement.
−Removed: The Company appealed the grant of summary judgment to the Court of Appeals on June 8, 2023.
−Removed: The Company is pursuing the appeal with respect to the first patent, with oral argument expected in the first quarter of 2025.
Second, the Court denied Spectrum’s motion to supplement its allegations of alleged antitrust violations, finding that if such an amendment were allowed, Spectrum’s claims would not survive a motion for summary judgment.
1 unchanged sentence
Spectrum did not appeal the District Court’s denial of its motion to amend.
+Added: The Company appealed the grant of summary judgment to the Court of Appeals on June 8, 2023.
+Added: On February 14, 2025, the Court of Appeals affirmed the District Court’s judgment.
+Added: The Court of Appeals mandate issued on March 24, 2025.
On February 7, 2024, the PTO issued a Final Written Decision regarding the second patent in the litigation, holding that claims 1, 3–8, 11, and 12 of U.S.
3 unchanged sentences
On September 15, 2023, Spectrum filed a separate petition for inter partes review of a third patent, which DNAG did not assert in the District Court.
−Removed: On March 26, 2024, the PTO issued a Decision Granting Institution of Inter Partes Review and scheduled oral argument for January 13 2025.
−Removed: On July 2, 2024, the Company filed a Motion to Amend the claims of the third patent, which remains pending.
−Removed: There have been no material changes to the risk factors disclosed in Item 1A, entitled “Risk Factors,” in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
+Added: On March 26, 2024, the PTO issued a Decision Granting Institution of Inter Partes Review.
+Added: On July 2, 2024, the Company filed a Motion to Amend the claims of the third patent and oral argument in this IPR took place on January 24, 2025.
+Added: On February 19, 2025, the PTO issued a Final Written Decision regarding the third patent in the litigation, granting the Company’s Motion to Amend as to cancelling the original claims, but denying the Company’s Motion to Amend as to adding proposed substitute claims.
+Added: NowDiagnostics Litigation
+Added: On November 14, 2024 the Company filed a complaint against NowDiagnostics, Inc.
+Added: ("NowDx"), Jody Berry ("Berry") and Janean Young ("Young") in the United States District Court for the Eastern District of Pennsylvania alleging misappropriation and misuse of the Company's proprietary information and trade secrets by NowDx, Berry and Young in violation of the Federal Defend Trade Secrets Act and the Pennsylvania Uniform Trade Secrets Act.
+Added: The complaint also alleges breach of contract and duty of loyalty by Young, unfair competition by NowDx, and tortious interference with contractual relations by Berry and NowDx.
+Added: NowDx filed Counterclaims against the Company on January 13, 2025 and the Company filed its Answer to the Counterclaims on February 3, 2025.
+Added: Young filed a Motion to Dismiss the claims against her, which was denied by the court on February 4, 2025.
+Added: NowDx, Berry, and Young agreed to a preliminary injunction which the Court entered on February 27, 2025.
+Added: The trial is scheduled for March 9, 2026.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.